Ho PT, et al. - In this cost-benefit analysis, researchers investigated if maintaining a malignant hyperthermia cart, stocked with dantrolene, in every maternity unit in the United States would be a cost-effective approach relative to a malignant hyperthermia cart readily available within the hospital vs an initial dantrolene dose of 250 mg. They estimated the expected number of lives saved, using a decision-tree model, and compared this benefit against the expected costs of the policy. They found that maintaining a fully stocked malignant hyperthermia cart with a full supply of dantrolene within 10 min of maternity units had no cost benefit. They recommended alternative strategies (eg, maintain a small supply of dantrolene on the maternity unit for starting treatment) be instituted by hospitals.